Document is current
Any future updates will be listed below
-
Authors
Oishi, Ritsuko
Kobayashi, Satoshi
Nagashima, Shuhei
Fukushima, Taito
Tezuka, Shun
Morimoto, Manabu
Ueno, Makoto
Maeda, Shin
- License Information
-
More Information
Article History
Received: 26 August 2024
Accepted: 25 March 2025
First Online: 9 April 2025
Declarations
:
: The study was approved by the institutional review board of the Kanagawa Cancer Center (ID: 2021-41) and was conducted according to the Declaration of Helsinki. The participants were given the opportunity to opt out of having their information published.
: Not applicable.
: ・S. Kobayashi received honoraria for speakers’ bureaus from AstraZeneca plc, MSD K.K., and Taiho Pharmaceutical Co., Ltd.・M. Ueno received grants from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, Eisai Co., Ltd., Novartis Pharma K.K., Astellas Pharma Inc., J-pharma Co., Ltd., DFP (Delta-Fly Pharma), Inc., Novocure GmbH, and Chiome Bioscience Inc., and honoraria for speakers’ bureaus from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., Yakult Honsha Co., Ltd., MSD K.K., Nihon Servier Co., Ltd., Ono Pharmaceutical Co., Ltd., Incyte Biosciences Japan GK, Chugai Pharmaceutical Co., Ltd., Boehringer Ingelheim GmbH, J-pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., and Novartis Pharma K.K.・The other authors declare no conflicts of interest.
